Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

[Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: review of the literature].

Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa Lyonnet D, Flahault C, Sultan S.

Bull Cancer. 2011 Feb;98(2):184-98. doi: 10.1684/bdc.2011.1309. Review. French.

2.

Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.

Carpenter KM, Eisenberg S, Weltfreid S, Low CA, Beran T, Stanton AL.

Health Psychol. 2014 Sep;33(9):1003-11. doi: 10.1037/a0032737. Epub 2013 Jun 17.

PMID:
23772886
3.

Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women's looking back on the pre-test period and a psychological evaluation.

Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E.

Genet Test. 2004 Spring;8(1):13-21.

PMID:
15140370
4.
5.

Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.

van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W.

J Clin Oncol. 2006 Aug 1;24(22):3672-7.

PMID:
16877736
6.

Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.

Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF.

Am J Med Genet A. 2003 Jun 15;119A(3):266-72.

PMID:
12784290
7.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):362-79. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144895
8.

[Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors].

Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa-Lyonnet D, Sultan S.

Bull Cancer. 2012 Jun;99(6):673-84. doi: 10.1684/bdc.2012.1590. French.

9.

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.

Breast Cancer Res Treat. 2002 May;73(2):97-112.

PMID:
12088120
10.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
11.

No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches.

Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S.

Genet Med. 2002 Sep-Oct;4(5):353-8.

PMID:
12394348
12.

Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.

Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, Chart P, Warner E.

CMAJ. 2001 Apr 3;164(7):1005-9.

13.

Understanding of BRCA1/2 genetic tests results: the importance of objective and subjective numeracy.

Hanoch Y, Miron-Shatz T, Rolison JJ, Ozanne E.

Psychooncology. 2014 Oct;23(10):1142-8. doi: 10.1002/pon.3537. Epub 2014 Apr 14.

PMID:
24733657
14.

No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.

Dorval M, Gauthier G, Maunsell E, Dugas MJ, Rouleau I, Chiquette J, Plante M, Laframboise R, Gaudet M, Bridge PJ, Simard J.

Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2862-7.

15.

The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.

Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti MA.

Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.

PMID:
24117034
16.

Benefit finding in response to BRCA1/2 testing.

Low CA, Bower JE, Kwan L, Seldon J.

Ann Behav Med. 2008 Feb;35(1):61-9. doi: 10.1007/s12160-007-9004-9. Epub 2008 Feb 15.

PMID:
18347905
17.

Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.

Vos J, Gómez-García E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.

Psychooncology. 2012 Jan;21(1):29-42. doi: 10.1002/pon.1864. Epub 2010 Nov 11.

PMID:
21072753
18.

Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A.

Patient Educ Couns. 2007 Jan;65(1):58-68. Epub 2006 Jul 26.

PMID:
16872788
19.

The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?

Beran TM, Stanton AL, Kwan L, Seldon J, Bower JE, Vodermaier A, Ganz PA.

Ann Behav Med. 2008 Oct;36(2):107-16. doi: 10.1007/s12160-008-9060-9. Epub 2008 Sep 12.

PMID:
18787910
20.

Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.

Wainberg S, Husted J.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1989-95. Review.

Supplemental Content

Support Center